INDUCTION AND SUPPRESSION OF NEOANGIOGENESIS

诱导和抑制新血管生成

• 批准号: 2647829
• 负责人: JEFFREY A GREENSPAN
• 金额: $ 10万
• 依托单位: MUNIN CORPORATION
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-18 至 1998-11-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2647829
• 关键词: angiogenesis; angiogenesis inhibitors; antineoplastics; cell line; cell migration; chemoattractants; drug screening /evaluation; neoplasm /cancer blood supply; protein structure function; transfection; vascular endothelium

DESCRIPTION: (Adapted from the Applicant's Abstract). This project will examine the ability of a recently described protein, Cyr61, to induce localized vascular neoangiogenesis and to develop assays with which to screen specific inhibitors of this activity. Neoangiogenesis plays a critical role in wound healing and also is necessary for tumor growth and metastasis. Thus, therapeutic inhibitors of Cyr61 could be marketable anti-cancer drugs. The specific aims of phase I are the following: (1) demonstration that this protein induces neoangiogenesis in vivo; (2) establishment of an in vitro assay based on this protein's anticipated ability to promote the migration of capillary progenitor cells that can be used to screen rapidly for candidate anti-neoangiogenesis drugs; (3) to identify mammalian cell lines deficient in this protein and to use them to demonstrate the ability of Cyr61 to promote the growth of tumor associated vasculature in vivo. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（改编自申请人摘要）。 该项目将 检查最近描述的蛋白质Cyr 61诱导 局部血管新生，并开发测定， 筛选这种活性的特异性抑制剂。 新血管生成在 在伤口愈合中起关键作用，也是肿瘤生长所必需的， 转移 因此，Cyr 61的治疗性抑制剂可能是可销售的 抗癌药 第一阶段的具体目标如下：（1） 证明该蛋白在体内诱导新血管生成;（2） 建立基于该蛋白预期的体外测定 促进毛细血管祖细胞迁移的能力， 用于快速筛选候选抗新生血管生成药物;（3） 鉴定这种蛋白质缺陷的哺乳动物细胞系，并将它们用于 证明Cyr 61促进肿瘤相关细胞生长的能力， 体内的脉管系统。 拟议商业应用：不可用